| MeSH term | MeSH ID | Detail |
|---|---|---|
| Dyslipidemias | D050171 | 7 associated lipids |
| Hashimoto Disease | D050031 | 1 associated lipids |
| Hyperparathyroidism, Primary | D049950 | 1 associated lipids |
| Diabetes Complications | D048909 | 4 associated lipids |
| Hypertension, Pregnancy-Induced | D046110 | 2 associated lipids |
| Scleroderma, Limited | D045745 | 1 associated lipids |
| Glucose Metabolism Disorders | D044882 | 3 associated lipids |
| Malnutrition | D044342 | 6 associated lipids |
| Irritable Bowel Syndrome | D043183 | 8 associated lipids |
| Mastocytoma | D034801 | 3 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hofbauer LC et al. | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. | 2001 | Cancer | pmid:11505389 |
| Ma YL et al. | Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. | 2001 | Endocrinology | pmid:11517184 |
| Bateman TA et al. | Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. | 2001 | J. Orthop. Res. | pmid:11518255 |
| Myoung H et al. | Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. | 2001 | J. Periodont. Res. | pmid:11519698 |
| Haynes DR et al. | The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. | 2001 | J Bone Joint Surg Br | pmid:11521937 |
| Marco-Mingot M et al. | Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. | 2001 | Clin. Genet. | pmid:11531977 |
| Allan GF et al. | Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. | 2001 | Steroids | pmid:11546554 |
| Raffai RL et al. | Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11553788 |
| Hocking LJ et al. | Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. | 2001 | Am. J. Hum. Genet. | pmid:11555792 |
| Pearse RN et al. | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11562486 |